TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company
Transcenta, Biologics, Antibody, Claudin 18.2
Our translational research generates PK, PD, Tox and immunogenicity data through validated quantitative platforms, and enables us to model clinical responses to our investigational agents for better understanding of PK/PD/Safety profiles, which guides design and conduct of clinical studies. We provide scientific inputs to best-in-class drug candidate selection and provide assessment of combination therapies with agents targeting different disease signaling pathways. We have platforms that allow us to generate and screen antibodies for target-detection using immunohistochemistry and to develop companion diagnostic assays for patient selection and stratification in clinical trials, which improves trial success by enrolling patients with high probability of response to the drug treatment in selected indications.